Prognostic role of Lipoprotein(a) in atherosclerotic cardiovascular disease risk from a perspective on current risk-stratification

This study is led by Professor. Jianjun Li (Cardiometabolic Center, State Key Laboratory of Cardiovascular Disease, FuWai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College) and Professor.  Yuanlin Guo (Cardiometabolic Center, State Key Laboratory of Cardiovascular Disease, FuWai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College). In their study, the researchers  assessed the relationship of current guideline-stratification of ASCVD with plasma Lp(a). 

With the renewal of the knowledge of ASCVD, the finer division of risk-stratification have been updated in current cholesterol guidelines. Lp(a) is an emerging predictor for ASCVD but little attention was paid to the association from a perspective on current risk-stratification. Professor. Li and Guo collaborate with their team highlighted the important role of Lp(a) in patients at different risk-stratification for risk of CVEs, suggesting that the higher the risk-stratification, the better the correlation of Lp(a) and CVEs. 

First, there was an upward trend in Lp(a) levels across the current guideline-refined risk groups of ASCVD, indicating that circulating Lp (a) might be higher in patients with a higher risk-stratification. Second, there was a significant increase in the incidence and risk of CVEs regardless of other risk factors in patients who had high Lp(a) or risk stratification, regarding Lp (a) in combination with ASCVD risk stratification in clinical management. Third, the value of Lp(a) elevation for CVEs risk prediction was evident in patients at VHR but not those at non-VHR. The measurement and management of Lp(a) may be more valuable and a lower Lp(a) cutoff value may contribute to further decrease of CVEs risk in those patients with VHR compared to patients at non-VHR.

“Lp(a) might be regarded as a lipid component worse than low-density lipoprotein and presented dissimilarity in risk of CVEs among patients at different risk stratification of ASCVD. The value of Lp(a) elevation, even within the normal range, on CVEs prediction was evident in patients at VHR but not in those at non-VHR” Professor. Li says.

See the article: 

Prognostic role of Lipoprotein(a) in atherosclerotic cardiovascular disease risk from a perspective on current risk-stratification

https://doi.org/10.1002/mco2.773